Fullhope Biomedical Co., Ltd
TTPEX:777329.85
TWD
-0.15
(-0.50%)
ISIN
TW0007773004
Return %
Stock
S&P 500
1Y
-17.43
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Chien Mou Li
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Taipei Taiwan
- IPO Date
- Sep 26, 2024
- Website
- fhb.com.tw
- Similar Companies
- Business
- Fullhope Biomedical Co., Ltd. is a Taiwan-based biotechnology company specializing in cellular immunotherapy, regenerative medicine, and precision clinical diagnostic services for oncology, autoimmune diseases, and degenerative conditions. Founded in 2012 and headquartered in Taipei, Taiwan, the company operates across the biopharmaceutical, medical testing, and contract manufacturing sectors, serving medical centers, academic research institutions, biopharmaceutical developers, and individual patients across the Asia-Pacific region. Fullhope Biomedical offers a comprehensive portfolio of products and clinical services structured across four principal segments: Cellular Immunotherapy and Regenerative Therapies, which includes autologous and allogeneic cell products such as Natural Killer (NK) cell therapies, Cytokine-Induced Killer (CIK) cell therapies, Gamma Delta T (γδ T) cell platforms, Chimeric Antigen Receptor (CAR)-modified cell candidates, and Mesenchymal Stem Cell (MSC) preparations for regenerative repair; Precision Medicine and Diagnostic Profiling, comprising multi-parameter immune functional assessments, circulating tumor cell (CTC) detection, immune repertoire sequencing, tumor biomarker assays, and individualized cancer drug sensitivity screenings; Cell Banking and Cryopreservation, providing proprietary processing and long-term storage of peripheral blood mononuclear cells, immune cells, and adult stem cells; and Contract Development and Manufacturing Organization (CDMO) Services, offering Good Tissue Practice (GTP) and PIC/S GMP-compliant cell processing, bioprocess optimization, quality testing, and clinical batch manufacturing for healthcare partners. In recent corporate developments, Fullhope Biomedical completed its public listing on the Emerging Stock Board of the Taipei Exchange under ticker 7773, enhancing its capitalization to accelerate translational research and commercial pipeline expansion. Furthermore, aligned with the regulatory adoption of Taiwan's Regenerative Medicine Act and Special Regulations for Cell Therapy, the company has expanded its strategic clinical trial partnerships with major university hospitals and tertiary medical centers, advanced the clinical evaluation of its proprietary gamma-delta T cell immunotherapy platform for solid tumors, and enlarged its GMP cell manufacturing capacity to support scaled domestic and cross-border biopharmaceutical collaborations.